NCT01540071

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

A Phase II Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Io Therapeutics · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.

Detailed description

Numerous studies in pre-clinical models and in human clinical trials have clearly established the potential for the use of rexinoids in the treatment and prevention of cancer. NRX 194204, a second generation rexinoid, is a highly potent and specific activator of RXRs (retinoid X receptors). Because NRX 194204 is significantly more selective for the RXRs relative to the RARs (retinoic acid receptors) than a first generation approved drug, it is associated with fewer adverse events in clinical use. This study seeks to investigate NRX 194204 monotherapy in patients with castration- and taxane- resistant prostate cancer.

Conditions

• Castration Resistant Prostate Cancer

Interventions

Type	Name	Description
DRUG	NRX 194204	NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day

Timeline

• Start date: 2011-08-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2012-02-28
• Last updated: 2021-05-14
• Results posted: 2021-05-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study